Literature DB >> 15219370

[Auto-immune-like disease post-bone marrow transplantation].

S Vinzio1, B Lioure, F Grunenberger, J-L Schlienger, B Goichot.   

Abstract

INTRODUCTION: Bone marrow transplantation (BMT) is based on destruction of the patient's bone marrow with rescue of haematopoietic stem cells from a donor. Chronic graft-vs-host disease (GVH) is the major complication post-BMT and mimics some autoimmune diseases, such as scleroderma, sicca syndrome, primary biliary cirrhosis and an increased prevalence of various autoantibodies. Other autoimmune-like manifestations have been reported as case reports or short series. The most common are myasthenia gravis, polymyositis, autoimmune cytopenias and Graves' disease or autoimmune hypothyroidism. CURRENT KNOWLEDGE AND KEY POINTS: These diseases occur mainly in association with chronic GVH. The pathophysiology of chronic GVH and other autoimmune-like diseases post-BMT remains poorly understood. Different mechanisms have been postulated. Most of the autoimmune events (either chronic GVH or more specific diseases) seem to be related to a poor or inadequate immunologic recovery post-BMT with an imbalance between autoregulatory and autoreactive lymphocytes. Microchimerism and molecular mimicry have been recently evocated. A minority of cases (autoimmune thyroid disorders) is attributed to the direct transfer of autoreactive cells from donor to patient (adoptive immunity). FUTURE PERSPECTIVES: Despite physiopathologic uncertainty, these autoimmune-like disorders post-BMT are an interesting model for primary autoimmune diseases.

Entities:  

Mesh:

Year:  2004        PMID: 15219370     DOI: 10.1016/j.revmed.2003.12.019

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  1 in total

1.  Graft-versus-host disease-related polymyositis.

Authors:  Helene Maillard-Lefebvre; Sandrine Morell-Dubois; Marc Lambert; Hilaire Charlanne; David Launay; Eric Hachulla; Ibrahim Yakoub-Agh; Pierre-Yves Hatron
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.